Utama › Limfoma Burkitt › Ohio › Cincinnati
Kajian klinikal Limfoma Burkitt di Cincinnati, OH
12 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi dalam dan sekitar Cincinnati (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi jauh
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi jauh
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Mengambil pesertaFasa 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Mengambil pesertaFasa 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mengambil pesertaFasa 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Mengambil pesertaFasa 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Mengambil pesertaFasa 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Mengambil pesertaFasa 1
- University of Cincinnati, Cincinnati
Kajian Limfoma Burkitt di bandar lain
- Houston, TX21 kajian
- Milwaukee, WI16 kajian
- Philadelphia, PA16 kajian
- New York City, NY14 kajian
- Chicago, IL14 kajian
- Atlanta, GA12 kajian
- Seattle, WA11 kajian
- Boston, MA10 kajian
- Durham, NC10 kajian
- Aurora, CO10 kajian
- Los Angeles, CA10 kajian
- Kansas City, MO10 kajian
Kajian lain di Cincinnati
- Kanser Paru-paru Bukan Sel Kecil35 kajian
- Kanser (semua jenis)27 kajian
- Kanser Payudara25 kajian
- Kegagalan Jantung24 kajian
- Kanser Kolorektal21 kajian
- Leukemia Mieloid Akut20 kajian
- Kanser Metastatik20 kajian
- Kanser Ovari19 kajian
- Kanser Paru-paru19 kajian
- Obesiti19 kajian
- Kanser Prostat18 kajian
- Mieloma Pelbagai17 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.